Table 1.

Immunohistochemical investigations of RD2D3 and cRD2D3 treatment on Aβ deposits and neuroinflammation. Treatment with neither RD2D3, nor cRD2D3 did reveal any increase or decrease in Aβ deposits (6E10), activated astrocytes (GFAP) or microglia (Iba-1). IR: immunoreactivity. Data are represented as mean ± SEM. IR: immunoreactivity (placebo N = 13, RD2D3 N = 14 and cRD2D3 N = 12).

	6E10 IR (%)		GFAP IR (%)		Iba-1 IR (%)
	Cortex	Hippocampus	Cortex	Hippocampus	Cortex	Hippocampus
Placebo	1.8 ± 0.7	2.5 ± 0.7	43.8 ± 2.0	39.8 ± 1.0	8.7 ± 1.7	11. 5 ± 1.1
RD2D3	1.0 ± 0.2	2.5 ± 0.5	40.6 ± 2.2	38.0 ± 1.2	8.1 ± 1.6	8.6 ± 1.3
cRD2D3	1.1 ± 0.2	4.2 ± 0.7	43.1 ± 1.8	39.5 ± 1.0	8.1 ± 1.6	10.2 ± 1.8